

Fiscal Year 2025 Department of Defense Peer Reviewed Medical Research Program (PRMRP)
Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Clinical Trial Award Go to: <ul style="list-style-type: none"> Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT942525PRMRPCTA	Assistant Professor level or above (or equivalent)	<ul style="list-style-type: none"> Supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of a disease or condition addressed in one of the congressionally directed FY25 PRMRP topic areas and FY25 PRMRP strategic goals. Proposed projects may range from small proof-of-concept trials through large-scale definitive trials. <i>Submission of a Letter of Intent is required prior to full application submission.</i> <i>Clinical trials are required. Animal studies not allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$8.0 million (M) for total costs. The maximum period of performance is 4 years. 	Pre-Application (Letter of Intent): June 9, 2025 5:00 p.m. Eastern time Application: July 21, 2025 11:59 p.m. Eastern time
Technology/Therapeutic Development Award Go to: <ul style="list-style-type: none"> Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: HT942525PRMRPTTDA	Assistant Professor level or above (or equivalent)	<ul style="list-style-type: none"> Supports the translation of promising preclinical findings into products for clinical applications including prevention, detection, diagnosis, treatment, and/or quality of life for a disease or condition related to one of the FY25 PRMRP topic areas and one of the FY25 PRMRP strategic goals. Supports product-oriented projects (e.g., device, drug, clinical guidelines). The product(s) to be developed may be a tangible item such as a pharmacologic agent (drugs or biologics) or device, or a knowledge-based product. <i>Submission of a Letter of Intent is required prior to full application submission.</i> <i>Clinical trials are not allowed.</i> 	<ul style="list-style-type: none"> The maximum allowable funding for the entire period of performance is \$3.5M for total costs. The maximum period of performance is 4 years. 	Pre-Application (Letter of Intent): June 9, 2025 5:00 p.m. Eastern time Application: July 21, 2025 11:59 p.m. Eastern time